Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
VentX expression in tumor-associated macrophages promotes phagocytosis and immunity against pancreatic cancers
Yi Le, … , Thomas Clancy, Zhenglun Zhu
Yi Le, … , Thomas Clancy, Zhenglun Zhu
Published June 23, 2020
Citation Information: JCI Insight. 2020;5(14):e137088. https://doi.org/10.1172/jci.insight.137088.
View: Text | PDF
Research Article Immunology

VentX expression in tumor-associated macrophages promotes phagocytosis and immunity against pancreatic cancers

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy that has no effective treatment. The tumor microenvironment (TME) of PDA employs a multitude of immune derangement strategies to protect PDA from immune elimination. Tumor-associated macrophages (TAMs) have been implicated in the pathogenesis of immune suppression of the PDA TME; however, its underlying mechanisms remained largely unknown. Using primary patient samples, our studies showed that, in comparison with macrophages isolated from normal pancreatic tissues, the phagocytosis activity of the PDA TAMs was significantly reduced. We found that the expression of homeobox protein VentX, a master regulator of macrophage plasticity, was significantly decreased in the PDA TAMs. We demonstrated that VentX was required for phagocytosis and that restoration of VentX expression in PDA TAMs promoted phagocytosis through the regulation of the signaling cascades involved in the process. Using an ex vivo culture model of primary human PDA, we showed that VentX-modulated TAMs transformed the PDA TME from a protumor milieu to an antitumor microenvironment by rectifying differentiation, proliferation, and activation of PDA-infiltrating immune cells. Using NSG-PDX models of primary human PDAs, we showed that VentX-modulated TAMs exerted strong inhibition on PDA tumorigenesis in vivo. Taken together, our data revealed a central mechanism underlying immune evasion of PDA and a potential novel venue to improve PDA prognosis.

Authors

Yi Le, Hong Gao, William Richards, Lei Zhao, Ronald Bleday, Thomas Clancy, Zhenglun Zhu

×

Figure 6

VentX-TAMs inhibits tumorigenesis of PDA in NSG-PDX models of primary human pancreatic cancers.

Options: View larger image (or click on image) Download as PowerPoint
VentX-TAMs inhibits tumorigenesis of PDA in NSG-PDX models of primary hu...
NSG-PDX models of primary human pancreatic cancers were generated by subcutaneous implantation of small pieces of primary human PDA on the dorsal side of NSG mice. The mice were then tail vein injected with VentX-TAMs or control GPF-TAMs. (A) Distribution of VentX-TAMs in lymph nodes. The CFSE-labeled VentX-transfected TAMs were tail vein injected into NSG-PDX mice with human PDA. 72 hours after injection, inguinal lymph nodes (iLN) from the tumor side or control side were removed from the mice, and single-cell suspensions were analyzed by flow cytometry. The percentage of CFSE-positive TAMs is shown. Data are shown as the mean ± SD of 3 independent experiments. *P < 0.05, paired Student’s t test. (B) The growth of the PDA in vivo was observed for up to 6 weeks, and the results of the treatment are shown. Data represent the mean of 7 independent experiments (n = 7). **P < 0.01, 2-way ANOVA with repeated measures.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts